Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09PTA
|
|||
| Former ID |
DIB002342
|
|||
| Drug Name |
HP-290
|
|||
| Synonyms |
Quilostigmine; NXX-066; UNII-2L1YNO4SQJ; 2L1YNO4SQJ; 139314-01-5; CHEMBL1243298; Quilostigmine [USAN:INN]; NXX 066; HP 290; AC1L30LY; Quilostigmine (USAN/INN); SCHEMBL28872; IIFRKALDATVOJE-GGAORHGYSA-N; BDBM50326265; (3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl 3,4-dihydro-2(1H)-isoquinolinecarboxylate; D03823; 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)-; NXX-066; QUILOSTIGMINE
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Discontinued in Phase 2 | [1] | |
| Company |
Astra AB; Hoechst AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27N3O2
|
|||
| Canonical SMILES |
CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)N4CCC5=CC=CC=C5C4)C)C
|
|||
| InChI |
1S/C23H27N3O2/c1-23-11-13-24(2)21(23)25(3)20-9-8-18(14-19(20)23)28-22(27)26-12-10-16-6-4-5-7-17(16)15-26/h4-9,14,21H,10-13,15H2,1-3H3/t21-,23+/m1/s1
|
|||
| InChIKey |
IIFRKALDATVOJE-GGAORHGYSA-N
|
|||
| CAS Number |
CAS 139314-01-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Acetylcholinesterase (AChE) | Target Info | Inhibitor | [2], [3] |
| KEGG Pathway | Glycerophospholipid metabolism | |||
| Cholinergic synapse | ||||
| Panther Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | ||||
| Pathwhiz Pathway | Phospholipid Biosynthesis | |||
| Pathway Interaction Database | ATF-2 transcription factor network | |||
| WikiPathways | Monoamine Transport | |||
| Biogenic Amine Synthesis | ||||
| Acetylcholine Synthesis | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006532) | |||
| REF 2 | NXX-066 in patients with Alzheimer's disease: a bridging study. Life Sci. 1999;64(14):1215-21. | |||
| REF 3 | Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based vi... J Med Chem. 2010 Sep 9;53(17):6490-505. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.